[HTML][HTML] Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
Z Zhou, Z Liu, Q Ou, X Wu, X Wang, Y Shao… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been
reported in diverse cancer types, including non-small cell lung cancer (NSCLC). The …
reported in diverse cancer types, including non-small cell lung cancer (NSCLC). The …
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC
JH Tchaicha, EA Akbay, A Altabef, OR Mikse, E Kikuchi… - Cancer research, 2014 - AACR
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …
[HTML][HTML] Detection of known and novel FGFR fusions in non–small cell lung cancer by comprehensive genomic profiling
A Qin, A Johnson, JS Ross, VA Miller, SM Ali… - Journal of Thoracic …, 2019 - Elsevier
Introduction Activation of the fibroblast growth factor receptor (FGFR) family through fusion
with various partners has been described in multiple cancer types, including NSCLC. FGFR …
with various partners has been described in multiple cancer types, including NSCLC. FGFR …
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
H Kotani, H Ebi, H Kitai, S Nanjo, K Kita, TG Huynh… - Oncogene, 2016 - nature.com
Targeted therapies are effective in subsets of lung cancers with EGFR mutations and
anaplastic lymphoma kinase (ALK) translocations. Large-scale genomics have recently …
anaplastic lymphoma kinase (ALK) translocations. Large-scale genomics have recently …
FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer
JJ Li, S Yan, Y Pan, Z Liu, Y Liu, Q Deng… - Cancer Biology & …, 2018 - Taylor & Francis
Targeting FGFRs is one of the most promising therapeutic strategies in squamous non-small
cell lung cancer (SQCC). However, different FGFR genomic aberrations can be associated …
cell lung cancer (SQCC). However, different FGFR genomic aberrations can be associated …
Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2
J Tanizaki, D Ercan, M Capelletti, M Dodge, C Xu… - Cancer research, 2015 - AACR
The discovery of oncogenic driver mutations and the subsequent developments in targeted
therapies have led to improved outcomes for subsets of lung cancer patients. The …
therapies have led to improved outcomes for subsets of lung cancer patients. The …
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective
A Quintanal-Villalonga, S Molina-Pinelo, P Yagüe… - Lung Cancer, 2019 - Elsevier
Objectives: Lung adenocarcinoma accounts for approximately half of lung cancer cases.
Twenty to 50% of tumors of this type harbor mutations affecting epidermal growth factor …
Twenty to 50% of tumors of this type harbor mutations affecting epidermal growth factor …
[HTML][HTML] Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
F Malchers, L Nogova… - The Journal of …, 2023 - Am Soc Clin Investig
The discovery of frequent 8p11-p12 amplifications in squamous cell lung cancer (SQLC) has
fueled hopes that FGFR1, located inside this amplicon, might be a therapeutic target. In a …
fueled hopes that FGFR1, located inside this amplicon, might be a therapeutic target. In a …
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
F Malchers, F Dietlein, J Schöttle, X Lu, L Nogova… - Cancer discovery, 2014 - AACR
The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in
squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified …
squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified …
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Lung cancer remains one of the leading causes of cancer-related death in developed
countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions …
countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions …